Related Experiment Video
Updated: Jul 19, 2026
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration
Paul N Baird1, F M Amirul Islam, Andrea J Richardson
1Centre for Eye Research Australia, University of Melbourne, East Melbourne, Victoria. pnb@unimelb.edu.au
Insights
The Y402H variant of the complement factor H (CFH) gene
Area of Science:
- Genetics and Ophthalmology
- Molecular Biology
- Population Genetics
Background:
- Age-related macular degeneration (AMD) is a leading cause of vision loss.
- The Y402H variant in the complement factor H (CFH) gene has been implicated as a risk factor in U.S. populations.
- Understanding the role of genetic factors in AMD is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the association of the Y402H variant with AMD in a non-U.S. population.
- To determine if the Y402H variant is linked to specific clinical phenotypes of AMD.
- To examine the relationship between the Y402H variant and age at diagnosis for AMD.
Main Methods:
- Case-control study involving 236 AMD patients and 144 controls.
- DNA extraction and genotyping of the Y402H variant using MALDI-TOF.
- Statistical analysis to assess risk, clinical associations, and age at diagnosis.
Main Results:
- The C allele of Y402H significantly increased AMD risk (OR 2.98).
- Risk was highest in neovascular AMD (OR 4.34).
- Homozygous CC individuals were diagnosed 7 years earlier than homozygous TT individuals.
Conclusions:
- The Y402H C allele is a significant risk factor for AMD, particularly neovascular AMD.
- This genetic variant influences disease onset and phenotype.
- Findings support the role of CFH in AMD pathogenesis across different populations.
Purpose:
Recent studies in U.S. populations have indicated that the Y402H variant of the complement factor H (CFH) gene contains a major risk susceptibility allele for age-related macular degeneration (AMD). This study was conducted to ascertain whether this is also true in a non-U.S. population and also whether the at-risk allele is associated with the clinical phenotype of disease and the age at diagnosis.
Methods:
Two hundred thirty-six unrelated individuals with AMD and 144 unrelated but ethnically matched control subjects were recruited and examined. All subjects completed a standard questionnaire, were given a fundus examination, and provided a blood sample for DNA extraction. Alleles of Y402H in the CFH gene were determined by use of a MALDI-TOF-based approach followed by statistical analysis.
Results:
Individuals with AMD who had at least one copy of the C allele of Y402H had an increased risk of disease (odds ratio [OR] 2.98; 95% confidence interval [CI] 1.81-4.93) compared with cases with the T allele. On subgroup analysis, this risk was found to be most significant in individuals with neovascular disease (OR 4.34; 95% CI 1.94, 9.71). In addition, individuals with neovascular disease who were homozygous CC presented with a significant 7.0-year earlier age at diagnosis relative to those individuals who were homozygous TT. The population-attributable risk for the C allele ranged between 47% to 69%, depending on the AMD disease subtype.
Conclusions:
The C allele of Y402H represents a significant risk factor in individuals with AMD, and this effect is most pronounced in individuals with neovascular disease.
